lessons learned from late phase failures and successes introduction
DESCRIPTION
Joint Conference of European Human Pharmacological Societies 11-12 April 2013 ~ Nice Sophia Antipolis FRANCE. Lessons learned from late phase failures and successes Introduction Dr Yves Donazzolo and Dr Maikel Raghoebar. Photo: Marcus Augustine. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Lessons learned from late phase failures and successes Introduction](https://reader036.vdocuments.net/reader036/viewer/2022062422/56813b84550346895da4acba/html5/thumbnails/1.jpg)
Joint Conference of European Human Pharmacological Societies
11-12 April 2013 ~ Nice Sophia Antipolis FRANCE
Lessons learned from late phase failures and successes
IntroductionDr Yves Donazzolo and Dr Maikel Raghoebar
Photo: Marcus Augustine
![Page 2: Lessons learned from late phase failures and successes Introduction](https://reader036.vdocuments.net/reader036/viewer/2022062422/56813b84550346895da4acba/html5/thumbnails/2.jpg)
Diagnosing the decline in the pharmaceutical R&D efficiency
PE
RS
PE
CT
IVE
S
2Dr Maikel Raghoebar & Dr Yves Donazzolo - Session 1 - Lessons learned from late phase failures and successes
Jack
W.
Sca
nnel
l - A
lex
Bla
nckl
ey –
Hel
en B
oldo
n –
Bria
n W
arrin
gton
Scanell et al, Nature Reviews Drug Discovery 11 (March 2012):191-200
![Page 3: Lessons learned from late phase failures and successes Introduction](https://reader036.vdocuments.net/reader036/viewer/2022062422/56813b84550346895da4acba/html5/thumbnails/3.jpg)
Can the pharmaceutical industry reduce attrition rates?
SUCCESS RATES FROM FIRST-IN-MAN TO REGISTRATION
Dr. Maikel Raghoebar & Dr Yves Donazzolo - Session 1 - Lessons learned from late phase failures and successes 3
NATURE REVIEWS | DRUG DISCOVERY
PE
RS
PE
CT
IVE
S
Ism
ail K
ola
- Jo
hn L
andi
s
I.Kola and J. Landis, Nature Reviews Drug Discovery 3 (2004): 711-715
![Page 4: Lessons learned from late phase failures and successes Introduction](https://reader036.vdocuments.net/reader036/viewer/2022062422/56813b84550346895da4acba/html5/thumbnails/4.jpg)
How to improve R&D productivity: the pharmaceutical industry’s grand challenge
Steven M. Paul - Daniel S. Mytelka - Christopher T. Dunwiddie -
Charles C. Persinger - Bernard H. Munos - Stacy R. Lindborg - Aaron L. Schacht
Dr. Maikel Raghoebar & Dr Yves Donazzolo - Session 1 - Lessons learned from late phase failures and successes 4
AN
AL
YS
IS
THE QUICK WIN, FAST FAIL DRUG DEVELOPMENT PARADIGM
NATURE REVIEWS | DRUG DISCOVERY
![Page 5: Lessons learned from late phase failures and successes Introduction](https://reader036.vdocuments.net/reader036/viewer/2022062422/56813b84550346895da4acba/html5/thumbnails/5.jpg)
Complexity of Innovative Drug Development
5Dr. Maikel Raghoebar & Dr Yves Donazzolo - Session 1 - Lessons learned from late phase failures and successes
Minimize bureaucracyInvest in Technology & PeopleIdentify tailor-made processes
“Business as usual” is not an option anymore
AN
AL
YS
IS
![Page 6: Lessons learned from late phase failures and successes Introduction](https://reader036.vdocuments.net/reader036/viewer/2022062422/56813b84550346895da4acba/html5/thumbnails/6.jpg)
Published Lessons Learned to challenge our speakers
Improvements of clinical trial design, selection of drug
targets, efficient execution of clinical trial design, etc.
Prioritize resources, avoid risks
Improve technical attrition
(translational target to medicine)
Develop/Hire experienced drug hunters
(every medicine had/has objectives to halt development)
6Dr. Maikel Raghoebar & Dr Yves Donazzolo - Session 1 - Lessons learned from late phase failures and successes
CO
NC
LU
SIO
N
![Page 7: Lessons learned from late phase failures and successes Introduction](https://reader036.vdocuments.net/reader036/viewer/2022062422/56813b84550346895da4acba/html5/thumbnails/7.jpg)
How can Clinical Pharmacology contribute to reduce attrition rates?
Human patient data and identification of
best indication in early clinical development
Tailoring for specific patient (sub)populations
(pathology, genotype, etc.)
Introduce creativity in translational and clinical research
Speakers: what else?
7Dr. Maikel Raghoebar & Dr Yves Donazzolo - Session 1 - Lessons learned from late phase failures and successes
CO
NC
LU
SIO
N